Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Retinoblastoma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An eye cancer that begins in the back of the eye (retina).
Oncolytic adenovirus armed with therapeutic genes
InactiveUS20060147420A1Improve efficiencyBiocideOrganic active ingredientsOncolytic adenovirusNucleotide
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Detection of protein conformations in single cells
InactiveUS7070943B2Avoid missing signalMicrobiological testing/measurementEnzymologyPhosphorylationChemical compound
Owner:BECTON DICKINSON & CO
Phospholipid ether analogs as cancer treatment agents and methods thereof
ActiveUS20070020178A1Improve the level ofX-ray constrast preparationsRadioactive preparation carriersMelanomaLymphatic Spread
The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
Owner:CELLECTAR
Anti-cancer antibodies with reduced complement fixation
ActiveUS20050202021A1Reduce complement fixationReduce pain levelsPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthBlastoma
The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Owner:MERCK PATENT GMBH
Targeted liposomes
The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs such as pemetrexed or irinotecan for treatment of cancer or drugs including atropine for treatment of organophosphate poisoning.
Owner:GEORGETOWN UNIV
Oncolytic adenovirus armed with therapeutic genes
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods of staining target chromosomal DNA employing high complexity nucleic acid probes
ActiveUS7115709B1Rapid and highly sensitive detectionEasy to analyzePeptide/protein ingredientsMicrobiological testing/measurementMetaphase chromosomeNucleic Acid Probes
Methods and compositions for staining based upon nucleic acid sequence that employ nucleic acid probes are provided. Said methods produce staining patterns that can be tailored for specific cytogenetic analyses. Said probes are appropriate for in situ hybridization and stain both interphase and metaphase chromosomal material with reliable signals. The nucleic acid probes are typically of a complexity greater than 50 kb, the complexity depending upon the cytogenetic application. Methods and reagents are provided for the detection of genetic rearrangements. Probes and test kits are provided for use in detecting genetic rearrangements, particularly for use in tumor cytogenetics, in the detection of disease related loci, specifically cancer, such as chronic myelogenous leukemia (CML), retinoblastoma, ovarian and uterine cancers, and for biological dosimetry. Methods and reagents are described for cytogenetic research, for the differentiation of cytogenetically similar but genetically different diseases, and for many prognostic and diagnostic applications.
Owner:RGT UNIV OF CALIFORNIA
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.
Owner:FUEYO JUAN +7
Methods of modulating smyd3 for treatment of cancer
InactiveUS20090191181A1Lower methylation levelsRelieve symptomsCompound screeningApoptosis detectionBladder cancerHepatocellular carcinoma
The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and / or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.
Owner:ONCOTHERAPY SCI INC
Anti-cancer antibodies with reduced complement fixation
ActiveUS7432357B2Easy to fixReduce pain levelsSugar derivativesPeptide/protein ingredientsMelanomaCell-mediated cytotoxicity
The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Owner:MERCK PATENT GMBH
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
ActiveUS8540968B2X-ray constrast preparationsRadioactive preparation carriersMelanomaLymphatic Spread
The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
Owner:CELLECTAR LLC
Oncolytic adenovirus armed with therapeutic genes
ActiveUS9061055B2Organic active ingredientsPeptide/protein ingredientsOncolytic adenovirusNucleotide
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Treatment of brain cancer with oncolytic adenovirus
The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.
Owner:DNATRIX +1
Method For The Treatment Of Proliferative Disorders Of The Eye
InactiveUS20110200662A1Inhibit cell proliferationLarge therapeutic indexBiocideSenses disorderUveitisMelanoma
The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin.
Owner:ONCOTX
Methods and Compositions for Treatment of Macular and Retinal Disease
InactiveUS20070259843A1Convenient treatmentImprove efficacyBiocideSenses disorderExudative age-related macular degenerationDisease cause
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
Owner:UNIV OF GEORGIA RES FOUND INC
Novel compositions and therapeutic methods
ActiveUS20170281667A1Good anti-inflammatory activityReduced VEGF expressionAntibacterial agentsOrganic active ingredientsAutoimmune responsesAutoimmune thyroid disease
The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and / or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and / or any disorder associated with inflammation, immunomodulation and microbial infection.
Owner:AYUVIS RES INC
Two promoters of asymmetric cell division regulation pathway of root tip stem cell of plant and application of two promoters
InactiveCN107460155AFacilitate regulatory pathwaysFully tap the economic valueCulture processPlant cellsShort rootAsymmetric cell division
The invention provides two flavonoid compounds, namely baicalein and scutellarein, of promoting a asymmetric cell division (ACD) regulation pathway of a root tip stem cell of a plant. The two compounds have effects of promoting SCR-SHR (scarecrow-short root) combination of an ACD active regulation complex of a root tip stem cell, does not influence RBR-SHR (retinoblastoma-related-short root) combination of a non-active complex and can activate NUC (nutcraker) expression of an ACD downstream key gene. At the same time, the invention provides an application of baicalein and scutellarein in preparing an SHR-SCR protein binding promoter and an NUC gene expression promoter. A secondary metabolism product of promoting ACD regulation of the root tip stem cell of the plant is found for the first time; a new biological effect of baicalein and scutellarein is found; an important tool is provided for an in-depth study of the stem cell regulation of the plant; and a new clue is provided for the development and application of a plant stem cell technology in industries of modern agriculture, biological medicine, hairdressing, health and the like.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Methods and compositions for treatment of macular and retinal disease
InactiveUS7259180B2Convenient treatmentImprove efficacyBiocideSenses disorderExudative age-related macular degenerationDisease cause
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
Owner:UNIV OF GEORGIA RES FOUND INC
Methods and compositions for modulating tumor suppression
The purification of native RB (retinoblastoma) as a complex, including P107, P130, and a 600 kDa subunit, termed MTAF600 (microtubule associated factor 600) is described. MTAF600 binds to RB regardless of the phosphorylation status of RB, and binds to RB without disrupting the interaction between RB and E2F. It is further shown that E2F and DP proteins co-purified with MTAF600 and RB, such that hypophosphorylated RB may gain access to E2F as a complex with MTAF600. In addition, MTAF600 binds to microtubules and plays a role in active repression of E2F-responsive genes, cell cycle arrest, and genomic stability. The sequence of MTAF600 is described herein, along with its binding properties to proteins such as RB and microtubules, and its sequence homology. Further, methods and reagents for assaying the presence of MTAF600 or mutants thereof, pharmaceutical formulations, and methods for treating disease are also described.
Owner:DANA FARBER CANCER INST INC
Compositions and methods for therapeutic use
A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
Owner:CANJI
Pharmaceutical composition of chloroquine and vincristine
ActiveCN104906099AReduce dosageLow toxicityOrganic active ingredientsAntineoplastic agentsSolid tumorVincristine
The invention discloses a pharmaceutical composition of chloroquine and vincristine. The pharmaceutical composition comprises 2-40mu M of chloroquine, 10nM of vincristine, or 5-50mu M of chloroquine and 20nM of vincristine. Chloroquine and vincristine of two dosages can synergically kill and inhibit multiple children solid tumors including retinoblastoma and nephroblastoma, and can be used as a chemotherapeutic medicine. Compared with an ordinary medicine, the pharmaceutical composition is small in dosage, low in toxicity and remarkable in effect in killing and inhibiting retinoblastoma and nephroblastoma.
Owner:HANGZHOU FANPU BIOTECH CO LTD
Methods of diagnosing amyotrophic lateral sclerosis (ALS)
InactiveUS20120213769A1Organic active ingredientsNervous disorderReference sampleAmyotrophic lateral sclerosis
A method of diagnosing amyotrophic lateral sclerosis (ALS) in a subject in need thereof is provided. The method comprising determining in cells of the subject at least one alteration in a sequence or expression level of Cytoplasmic FMR Interacting Protein (CyFIP2; Accession AF160973) and / or Retinoblastoma Binding Protein 9 (RbBP9; Accession AF039564), wherein an altered sequence or expression of the sequence or expression level of the CyFIP2; Accession AF160973) or Retinoblastoma Binding Protein 9 (RbBP9; Accession AF039564) as compared to a control reference sample from a non-ALS subject, is indicative of ALS. The present teachings may be implemented in screening for novel anti-ALS medicaments and for treating ALS.
Owner:RAMOT AT TEL AVIV UNIV LTD
Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
ActiveUS9988386B2Good effectMechanism is preventedSenses disorderOrganic chemistryDiabetic retinopathyUveitis
The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and / or preventing diseases associated with abnormal or pathological angiogenesis and / or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
Owner:KALA BIO INC
Methods and compositions for modulating tumor suppression
The purification of native RB (retinoblastoma) as a complex, including P107, P130, and a 600 kDa subunit, termed MTAF600 (microtubule associated factor 600) is described. MTAF600 binds to RB regardless of the phosphorylation status of RB, and binds to RB without disrupting the interaction between RB and E2F. It is further shown that E2F and DP proteins co-purified with MTAF600 and RB, such that hypophosphorylated RB may gain access to E2F as a complex with MTAF600. In addition, MTAF600 binds to microtubules and plays a role in active repression of E2F-responsive genes, cell cycle arrest, and genomic stability. The sequence of MTAF600 is described herein, along with its binding properties to proteins such as RB and microtubules, and its sequence homology. Further, methods and reagents for assaying the presence of MTAF600 or mutants thereof, pharmaceutical formulations, and methods for treating disease are also described.
Owner:DANA FARBER CANCER INST INC
Novel Compounds and Uses Thereof
ActiveUS20160137646A1Good effectMechanism is preventedSenses disorderOrganic chemistryDiabetic retinopathyUveitis
The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and / or preventing diseases associated with abnormal or pathological angiogenesis and / or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
Owner:KALA BIO INC
Direct and selective inhibition of MDM4 for treatment of cancer
ActiveUS10767182B2Easy to achieve pharmacologicallyFaster to introduce into the clinicOrganic active ingredientsSplicing alterationBlastomaMelanoma
The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
Owner:AGENCY FOR SCI TECH & RES +2
Application of GSK503 in preparing drug for treating RB (Retinoblastoma)
InactiveCN106692152AGrowth inhibitionEffective therapeutic concentrationOrganic active ingredientsAntineoplastic agentsTreatment fieldWilms' tumor
The invention belongs to the field of treating RB (Retinoblastoma), and particularly relates to application of GSK503 in preparing a drug for treating the RB. In the drug, the final concentration of the GSK503 is greater than or equal to 1 mu M. The GSK503 is a novel EZH2 (Enhancer of Zeste Homolog 2) small-molecule inhibitor, and an applicant experimentally finds that the GSK503 is capable of remarkably inhibiting the growth of the RB, and the methylation degree of H3K27me3 in cells is reduced through inhibiting the EZH2, so that cancer suppressor genes can be in re-expression, and the effect of inhibiting the tumor growth is reached. Effective treatment concentration can be reached when the final concentration of the GSK503 reaches 1 mu M, the use effect of the drug is increased while the concentration is increased, and the growth of the RB can be remarkably inhibited.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Methods of Treating Ocular Disorders
InactiveUS20200093852A1Organic active ingredientsSenses disorderRetinitis pigmentosaOcular inflammation
This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.
Owner:BETA THERAPEUTICS PTY LTD
Animal models of retinal tumorigenesis
Complimentary animal models for retinoblastoma which recapitulate conditions found in the eye of human retinoblastoma patients in an animal are provided. These models are generated by introducing an agent capable of giving rise to a retinoblastoma into the developing eye of an immunologically naive animal. In one model the agent comprises cells which are capable of giving rise to a retinoblastoma. In another model the agent comprises a vector capable of expressing an oncogene which, when expressed in a transfected cell, can give rise to a cell mass that mimics the early stages of retinoblastoma formation. These models can be used to study retinoblastoma and screen for, or characterize, inhibitory agents. These models may also be used to study the influence of genotype or engineered genes or gene deficiencies (knock-outs) on the development of retinoblastoma.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Urea derivatives and uses thereof
The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and / or preventing diseases associated with abnormal or pathological angiogenesis and / or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
Owner:KALA PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com